Rayner accelerates momentum in the US with strategic Anikavisc OVD deal
Posted on 2/03/2026
Rayner today announced it has acquired the United States distribution rights to Anikavisc, the ophthalmic viscosurgical device (OVD), from Visco Technologies Inc – a move that strengthens the company’s US cataract ecosystem and advances its mission to deliver a truly comprehensive portfolio of solutions.
Anikavisc OVD is used intraoperatively to protect the corneal endothelium, maintain anterior chamber depth and enable controlled surgical manipulation. The cohesive formula is designed to deliver consistent performance and surgical efficiency.
The acquisition comes at a pivotal moment for Rayner, as the company celebrates the US launch of its FDA-approved Sophi phaco platform and continues to expand access to its portfolio, including the RayOne EMV Toric IOL. With the PMA for RayOne Galaxy – the world’s first AI-designed spiral IOL – submitted, Rayner is positioning itself to offer a comprehensive, bundle-ready portfolio in 2026 – spanning premium and monofocal IOLs, OVD and advanced phaco technology.
“We’re excited about what this acquisition means for our US customers,” said Scott Corning, Vice President Americas at Rayner. “Anikavisc customers will see no changes to their current arrangements, but its reach and support will grow through our direct sales team from today. This also allows us to offer a fully bundled cataract solution, simplifying orders and streamlining purchasing, and delivers even greater value through one dedicated partner committed to innovation in cataract surgery.”
For more information, speak to your Rayner representative or visit www.rayner.com.
About Rayner:
Since the implantation of the first Rayner intraocular lens by Sir Harold Ridley in 1949, Rayner has had the goal to improve vision and restore sight worldwide. Today, Rayner’s mission remains to deliver innovative and clinically superior ophthalmic products that respond to the expectations of our global customers to improve the sight and quality of life of their patients.
Headquartered in Worthing, United Kingdom, Rayner markets its medical devices, pharmaceuticals, and digital solutions globally through a network of distributors and includes direct sales teams in the United Kingdom, Eire, USA, Canada, Brazil, India, Poland, Australia, Germany, Austria, Switzerland, France, Italy, Spain, and Portugal.
Not all Rayner products are approved for sale in every country. Please contact your local Rayner distributor for details of which products are available in your area.
©2026 Rayner Group, all rights reserved. ‘Rayner’ ‘RayOne’ ‘EMV’ ‘Sophi’ and ‘Galaxy’ are proprietary marks of the Rayner Group. All other trademarks are property of their respective owners. Rayner, The Ridley Innovation Centre, 10 Dominion Way, Worthing, West Sussex, BN14 8AQ. Registered in England: 615539 | EC 2026-16 EN